Showing results (1-10 of 79) with videos related to

Sort By:
Pageof 8
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 28, 2012
In search of a real "targeted" therapy for thyroid cancerMarcia S Brose
Current Oncology Reports|March 2, 2006
Her-2 targeted therapy: beyond breast cancer and trastuzumabKeith T Flaherty, Marcia S Brose
Journal of the Advanced Practitioner in Oncology|July 19, 2018
The Challenges of Clinical Research in Rare Cancers: Bevacizumab Use in Low-Grade Serous Ovarian and Primary Peritoneal CancersCarolyn Grande, Constance Visovsky, Marcia S Brose
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 28, 2010
Targeting vascular endothelial growth factor receptor in thyroid cancer: the intracellular and extracellular implicationsStephen M Keefe, Marc A Cohen, Marcia S Brose
Seminars in Oncology|March 1, 2014
Management of sorafenib-related adverse events: a clinician's perspectiveMarcia S Brose, Catherine T Frenette, Stephen M Keefe, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 15, 2017
Effect of Age on the Efficacy and Safety of Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer in the Phase III SELECT TrialMarcia S Brose, Francis P Worden, Kate L Newbold, et al.
Clinical Pharmacokinetics|March 4, 2023
Population Pharmacokinetics and Exposure-Response Analysis for the Phase 3 COSMIC-311 Trial of Cabozantinib for Radioiodine-Refractory Differentiated Thyroid CancerNeang S Ly, Jing Li, Raffaella Faggioni, et al.
Thyroid : Official Journal of the American Thyroid Association|August 8, 2014
A phase I study of cabozantinib (XL184) in patients with differentiated thyroid cancerMaria E Cabanillas, Marcia S Brose, Jaymes Holland, et al.
Endocrine-Related Cancer|June 15, 2012
RAP1GAP inhibits cytoskeletal remodeling and motility in thyroid cancer cellsXiaoyun Dong, Waixing Tang, Stephen Stopenski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 2019
Analysis of Biomarkers and Association With Clinical Outcomes in Patients With Differentiated Thyroid Cancer: Subanalysis of the Sorafenib Phase III DECISION TrialMarcia S Brose, Martin Schlumbeger, Michael Jeffers, et al.
Pageof 8